Results 211 to 220 of about 492,732 (252)
Some of the next articles are maybe not open access.
American Journal of Drug Delivery, 2006
▲ Metformin extended release (metformin ER) is a novel gastric-retentive formulation of the antihyperglycemic agent that can be administered once daily. The polymer matrix of the metformin ER 500mg tablet swells in gastric fluid, causing it to be retained in the stomach in the fed state.
Rachel H Foster, Susan J Keam
+5 more sources
▲ Metformin extended release (metformin ER) is a novel gastric-retentive formulation of the antihyperglycemic agent that can be administered once daily. The polymer matrix of the metformin ER 500mg tablet swells in gastric fluid, causing it to be retained in the stomach in the fed state.
Rachel H Foster, Susan J Keam
+5 more sources
Extended-Release Formulations in Epilepsy
Journal of Child Neurology, 2007In the past years, the extended-release antiepileptic drug formulations have been developed and then approved for the treatment of many types of epilepsy. Among these extended-release formulations of antiepileptic drugs, the main drugs are valproic acid, carbamazepine, and phenytoin.
Verrotti, Alberto +4 more
openaire +4 more sources
CNS Drugs, 2009
Quetiapine is an atypical antipsychotic agent with well established efficacy and tolerability in the acute and maintenance treatment of adults with schizophrenia. The extended-release formulation of quetiapine (quetiapine XR) was developed to provide more convenient once-daily administration, as well as allowing simple and rapid dose escalation, with ...
Claudine M, Baldwin, Lesley J, Scott
openaire +2 more sources
Quetiapine is an atypical antipsychotic agent with well established efficacy and tolerability in the acute and maintenance treatment of adults with schizophrenia. The extended-release formulation of quetiapine (quetiapine XR) was developed to provide more convenient once-daily administration, as well as allowing simple and rapid dose escalation, with ...
Claudine M, Baldwin, Lesley J, Scott
openaire +2 more sources
CNS Drugs, 2010
Pramipexole extended release (ER) is a non-ergolinic dopamine receptor agonist available for use as a once-daily oral treatment for the signs and symptoms of early and advanced idiopathic Parkinson's disease. Once-daily pramipexole ER and three times-daily pramipexole immediate release (IR) have similar exposure over 24 hours.
Claudine M, Chwieduk, Monique P, Curran
openaire +2 more sources
Pramipexole extended release (ER) is a non-ergolinic dopamine receptor agonist available for use as a once-daily oral treatment for the signs and symptoms of early and advanced idiopathic Parkinson's disease. Once-daily pramipexole ER and three times-daily pramipexole immediate release (IR) have similar exposure over 24 hours.
Claudine M, Chwieduk, Monique P, Curran
openaire +2 more sources
Niacin Extended-Release/Simvastatin
Drugs, 2008Niacin extended-release (ER)/simvastatin is a once-daily, fixed-dose combination of the HMG-CoA reductase inhibitor simvastatin and an ER formulation of niacin (a B-complex vitamin). In healthy volunteers who were given niacin ER/simvastatin 2000 mg/40 mg, niacin exposure was similar to that with niacin ER 2000 mg, while simvastatin exposure was ...
Mark, Sanford, Monique P, Curran
openaire +2 more sources
Extended-Release Intramuscular Naltrexone
Drugs, 2006An extended-release intramuscular formulation of naltrexone that provides sustained release of the drug over a 28-day period has been developed with the aim of improving treatment adherence in patients treated with naltrexone for alcohol dependence.
Tracy, Swainston Harrison +2 more
openaire +2 more sources
Extended-Release Dipyridamole/Aspirin
Drugs, 1999The fixed-dose combination of extended-release dipyridamole/aspirin (Aggrenox/Asasantin Retard) combines 2 antiplatelet agents with different mechanisms of action. The combination reduced thrombus formation in human and animal models. Coadministration of extended-release dipyridamole and aspirin in healthy volunteers had no significant effects on the ...
P S, Hervey, K L, Goa
openaire +2 more sources
An Overdose of Extended-Release Guanfacine
Pediatric Emergency Care, 2013Extended-release guanfacine is a centrally acting α2-adrenergic agonist that was recently approved for treatment of attention-deficit/hyperactivity disorder. The following is a case discussion of a 12-year-old boy with attention-deficit/hyperactivity disorder and Tourette syndrome, who presented 18 hours after ingestion of 3 times his usual dose of ...
Daniel M, Fein +2 more
openaire +2 more sources
Dalfampridine Extended Release
CNS Drugs, 2010Dalfampridine extended release (ER) is an orally administered formulation of dalfampridine (fampridine, 4-aminopyridine), a potassium channel antagonist indicated for the improvement in walking ability in patients with multiple sclerosis (MS). Oral dalfampridine ER improved walking ability in patients with MS in three randomized, double-blind trials of
Claudine M, Chwieduk, Gillian M, Keating
openaire +2 more sources
Pediatric Drugs, 2012
Paliperidone, the major active metabolite of risperidone, is an atypical antipsychotic agent formulated as an extended-release (ER) tablet suitable for once-daily oral administration. Paliperidone ER is approved for the treatment of adolescents aged 12-17 years with schizophrenia in the US (the focus of this review).
openaire +2 more sources
Paliperidone, the major active metabolite of risperidone, is an atypical antipsychotic agent formulated as an extended-release (ER) tablet suitable for once-daily oral administration. Paliperidone ER is approved for the treatment of adolescents aged 12-17 years with schizophrenia in the US (the focus of this review).
openaire +2 more sources